Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07250035Phase 3Not Yet Recruiting

Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy

Role: collaborator

NCT02544087Not ApplicableUnknown

Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction

Role: collaborator

NCT01636154Not ApplicableCompleted

Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations

Role: collaborator

All 3 trials loaded